# Australian Technical Advisory Group on Immunisation (ATAGI)

## Summary of the 106th meeting, 17 July 2024

### Respiratory syncytial virus (RSV)

* ATAGI reviewed and discussed a model that is being developed to help inform decisions about the optimal RSV prevention program for Australia, considering both RSV vaccines and monoclonal antibodies.

### Pneumococcal disease

* ATAGI reviewed and discussed an update from the pneumococcal subgroup on an updated childhood pneumococcal vaccination schedule for Australia.

### Mpox

* ATAGI reviewed and endorsed its [interim statement on mpox vaccination](https://www.health.gov.au/resources/publications/atagi-interim-statement-on-the-use-of-vaccines-for-prevention-of-mpox-in-2024?language=en) and boosters for at-risk groups, which has been published on the Department of Health and Aged Care’s website.
* ATAGI reviewed the evidence on the need for booster doses of vaccine for protection against mpox. ATAGI does not recommend booster doses of the mpox vaccine for people fully vaccinated with 2 doses at this time, including those who are severely immunocompromised.
* ATAGI considered that the mpox vaccine is effective. At-risk people who have not yet received the full 2 doses are encouraged to do so. ATAGI recommendations on vaccination are published in the [mpox chapter](https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/mpox-previously-known-as-monkeypox) of the Australian Immunisation Handbook.
* ATAGI will consider broadening the at-risk group that are recommended to receive primary preventative vaccination against mpox at its next meeting in August 2024.
* ATAGI will continue to monitor the mpox epidemiology in Australia and update its advice including the need for booster doses, if required.

### Influenza

* ATAGI noted that a statement regarding the transition to trivalent seasonal influenza vaccines in Australia will be endorsed out of session prior to publication on the Department of Health and Aged Care’s website.

### Pharmaceutical Benefits Advisory Committee (PBAC) advice

* ATAGI received updates from vaccine evaluation groups that are preparing ATAGI advice to the PBAC on vaccines that are being considered for the National Immunisation Program (NIP).
* ATAGI received an update from the PBAC Secretariat regarding recent consideration of vaccines for inclusion on the NIP.

### Department updates

* ATAGI received an update from the interim Australian Centre for Disease Control (CDC) on avian influenza pandemic preparedness.
* ATAGI noted progress on development of the National Immunisation Strategy by the interim CDC.
* ATAGI received an update from the Therapeutic Goods Administration (TGA) on vaccines that are [currently under evaluation for registration in Australia](https://www.tga.gov.au/resources/prescription-medicines-under-evaluation).

### Resources

* ATAGI’s membership, terms of reference and declaration of interest information is available on the [Department of Health and Aged Care website](https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi?language=und).